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Abstract
Ebola virus (EBOV) is the causative agent of severe hemorrhagic fever in primates, with human case fatality rates up to 90%.
Today, there is neither a licensed vaccine nor a treatment available for Ebola hemorrhagic fever (EHF). Single monoclonal
antibodies (MAbs) specific for Zaire ebolavirus (ZEBOV) have been successfully used in passive immunization experiments in
rodent models, but have failed to protect nonhuman primates from lethal disease. In this study, we used two clones of
human-mouse chimeric MAbs (ch133 and ch226) with strong neutralizing activity against ZEBOV and evaluated their
protective potential in a rhesus macaque model of EHF. Reduced viral loads and partial protection were observed in animals
given MAbs ch133 and ch226 combined intravenously at 24 hours before and 24 and 72 hours after challenge. MAbs
circulated in the blood of a surviving animal until virus-induced IgG responses were detected. In contrast, serum MAb
concentrations decreased to undetectable levels at terminal stages of disease in animals that succumbed to infection,
indicating substantial consumption of these antibodies due to virus replication. Accordingly, the rapid decrease of serum
MAbs was clearly associated with increased viremia in non-survivors. Our results indicate that EBOV neutralizing antibodies,
particularly in combination with other therapeutic strategies, might be beneficial in reducing viral loads and prolonging
disease progression during EHF.
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Introduction
Ebola virus (EBOV) has a non-segmented, single strand
negative-sense RNA genome and, together with Marburg virus,
constitutes the family Filoviridae [1]. EBOV causes severe
hemorrhagic fever in humans and nonhuman primates (NHPs)
with the highest human case fatality rates among hemorrhagic
fever viruses. Currently, there is neither an effective prophylaxis
nor treatment available for Ebola hemorrhagic fever (EHF). While
all Marburg virus isolates currently belong to a single virus species,
multiple EBOV species have been described [1,2]. Zaire ebolavirus
(ZEBOV), first identified in 1976, is the most virulent species with
case fatality rates in humans approaching 90% and almost 100%
lethality in experimental macaque models [1], the current gold
standard animal model among several established ZEBOV disease
models [3].
The EBOV transmembrane glycoprotein (GP) is responsible for
both receptor binding and fusion of the virus envelope with the
host cell membrane [4,5], and the only known target for
neutralizing antibodies against this virus. The presence of
EBOV-neutralizing antibodies was confirmed in the sera of
convalescent patients and experimentally infected NHPs [6,7].
The protective efficacy of passive immunization with hyperim-
mune sera or purified polyclonal antibodies was evaluated using
rodent models and shown to be effective in mice and guinea pigs,
whereas evidence of protective efficacy in primates, including
humans, remains elusive [6,7,8]. In contrast, we have shown that
certain GP-specific antibodies enhance filovirus infection in vitro,a
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that convalescent serum, hyperimmune serum, and serum from
vaccinated animals contain a mixture of neutralizing, enhancing,
and neutral antibodies [9–11]. Therefore, it seems possible that
ADE may diminish the efficacy of neutralizing antibodies [10,12]
and thus polyclonal serum may not aid in passive immune therapy
for EBOV. To reduce the potential risks and inherent disadvan-
tages in using whole polyclonal serum for passive immune therapy
against EHF, the use of well-defined and characterized monoclo-
nal antibodies (MAbs) seems more promising and perhaps better
justified. Additionally, MAb production is easier to scale up with
keeping the quality consistent while preparation of polyclonal
serum is not. This is an important factor for commercial
production of emergency immunotherapeutics. Quantities of any
particular polyclonal serum are finite and serum from different
animals would have to be pooled for a large supply.
Multiple ZEBOV GP-specific MAbs, including neutralizing
antibodies, have been generated in the past and several MAb
epitopes have been identified [13–16]. In particular, the
recombinant human MAb KZ52, which was generated using
phage display libraries constructed from RNA derived from
convalescent ZEBOV patients [13], was shown to be protective in
rodent models [17]; however, this MAb failed to protect rhesus
macaques from lethal ZEBOV challenge even when the animals
were given a high dose of the MAb (50 mg/kg) twice (1 day before
and 3 days after challenge) [18]. We have generated two mouse
MAbs, ZGP133/16.3 and ZGP226/8.1, that seem to recognize
unique epitopes in GP, compared to MAb KZ52 [15,16]. Pre- and
post-exposure treatment with each of the two MAbs in rodent
disease models resulted in complete or partial protection and
sterile immunity in several of the pre-exposure treated animals
[15,19].
In this study, we genetically modified these two MAbs to create
human-mouse chimeric MAbs (ch133 and ch226) and evaluated
their protective potential in the rhesus macaque model of lethal
ZEBOV infection. Prophylactic treatment with MAbs ch133 and
ch226 combined intravenously resulted in reduced viral loads and
partial protection, indicating that antibody therapy might have
beneficial effects in EHF.
Results
MAbs ch133 and ch226 neutralize ZEBOV in vitro
In a previous study, we have identified different amino acid
residues important for the neutralizing activity of the two mouse
MAbs, ZGP133/16.3 and ZGP226/8.1, using a surrogate virus
system [15]. All escape mutants selected in the presence of
ZGP133/3.16 contained a single amino acid substitution at
position 549 in the ZEBOV GP. In contrast, for ZGP226/8.1
three different escape mutants were isolated containing amino acid
substitution at position 134, 194, or 199 in the ZEBOV GP,
suggesting that this antibody recognizes a different conformational
epitope. Mapping of these epitopes, together with that of KZ52,
on the 3-D structure of the ZEBOV GP molecule indicates that
these MAbs likely bind to different epitopes, although the ZGP133
epitope may partially overlap with that of KZ52 (Figure 1).
To evaluate the protective efficacy in nonhuman primates, we
converted ZGP133/16.3 and ZGP226/8.1 into the human-mouse
chimeric MAbs ch133 and ch226. MAb ch61 specific for the
influenza virus hemagglutinin (HA) was generated as a control
antibody. The neutralizing activities of chimeric MAbs ch133 and
ch226 were analyzed in vitro by performing a focus reduction
neutralization test [20]. Both MAbs significantly reduced the
infectivity of ZEBOV in Vero E6 cells in a dose-dependent
manner (Figure 2), whereas the negative control MAb (ch61) did
not. The 50% inhibitory concentrations of ch133 and ch226 were
1.6 and 2.1 mg/ml, respectively. These values were similar to those
of the original mouse MAbs (3.2 and 0.8 mg/ml, respectively) [19],
indicating that genetic modification of these MAbs did not
significantly affect their ability to neutralize ZEBOV in vitro.
Protective efficacy in nonhuman primates
The stability of the chimeric MAb was first tested in vivo by
monitoring serum antibody levels in rhesus macaques that
received 50 mg of the antibody intraveniously. The MAb half-
life time in the serum was 3–4 days (data not shown). We next
sought to evaluate the prophylactic efficacy of both MAbs
combined in the well-established rhesus macaque model of EHF.
Three rhesus macaques (EBO1, EBO2, and EBO3) were
intraveniously treated with a mixture of MAbs ch133 and ch226
Figure 1. Locations of MAb epitopes. The trimeric structure of GP
was constructed using the Discovery Studio 2.5 program (Accelrys, Inc.)
based on the crystal structure of ZEBOV GP (PDB code: 3CSY). This
structure lacks amino acid residues at positions 190–213, 311–312, 464–
501, and 600–632, because no electron density was observed for these
residues [16]. The molecular surfaces of the GP trimer are shown in side
(A) and top (B) views. While one monomer is depicted as both subunits,
GP1 (yellow) and GP2 (brown), the other two monomers are colored
gray. The amino acid residues identified in escape mutants at positions
134 (ZGP226/8.1; ch226) and 549 (ZGP133/3.16; ch133) are shown in red
and green, respectively. The epitope recognized by MAb KZ52 in the
crystal structure of the GP-MAb complex is highlighted in pink.
doi:10.1371/journal.pone.0036192.g001
Figure 2. Chimeric MAbs neutralize ZEBOV. The indicated
concentrations of MAbs were incubated with 200 focus-forming units
of ZEBOV for 1 hour at 37uC and subsequently inoculated onto
monolayers of Vero E6 cells in a 48-well plate. After incubation for 4
days at 37uC, cells were fixed and removed from BSL4 using standard
operating procedures. Foci were stained with an anti-VP40 rabbit serum
and a FITC-conjugated anti-rabbit IgG antibody, counted and titers
were determined.
doi:10.1371/journal.pone.0036192.g002
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72 hours after challenge with a lethal dose of ZEBOV, strain
Kikwit (10
3 plaque-forming units). A control animal (CTRL) was
identically challenged and treated at the same time points with
MAb ch61 by the same route and dose. Animals CTRL and
EBO1 developed fulminant EHF with viremia levels exceeding
10
4 50% tissue culture infectious dose (TCID50) equivalents/ml
prior to day 8 and had to be euthanized on days 7 and 8,
respectively (Figure 3A). This is a normal disease progression for
rhesus macaques infected with a lethal dose of ZEBOV. Animal
EBO2 showed a delayed onset of clinical signs and prolonged time
to death with viremia levels still below 10
4 TCID50/ml on day 8
(Figure 3B), although it had to be euthanized with characteristic
signs of EHF on day 11. Furthermore, virus titers in liver, spleen,
and adrenal gland were more than 1 log higher in the control
animal (CTRL) compared to EBO2 (Table 1), again showing the
delayed disease progression in this animal. Animal EBO3 was
protected from clinical disease and survived. This animal had only
very low level viremia detected by qRT-PCR on day 8 (Figure 3A);
however, virus isolation was negative (Figure 3B). In addition, the
survivor EBO3 showed no significant ZEBOV-specific changes in
blood chemistry or hematology throughout the study; its liver
enzyme levels (i.e. alanine aminotransferase (ALT)), as well as
platelet counts, were always within the normal range (Figures 3C
and 3D). To exclude viral escape under neutralizing pressure, we
sequenced viral RNA isolated from blood collected on days 8
(EBO1) and 11 (EBO2). No mutation was found in the GP genes,
indicating that virus escape did not occur as previously described
for both MAbs in vitro [15].
Serum antibody levels in treated nonhuman primates
MAb concentrations in the serum samples collected throughout
the experiment were monitored using enzyme-linked immunosor-
bent assay (ELISA). MAb concentrations (ch133 and ch226) on
days 1–5 after challenge were maintained above 75 mg/ml, but
drastically decreased to almost undetectable levels in animals
EBO1 and EBO2 on day 8 (Figure 4A). The rapid decrease in
serum MAb concentrations was timely associated with increased
Figure 3. Hallmark laboratory parameters after ZEBOV challenge. Viral RNAs in the blood samples were detected as described in Materials
and Methods (A). Virus titers in the blood samples collected 8 days after challenge were determined as TCID50 in Vero E6 cells (B). For CTRL, titers for
the sample collected on day 7 are shown. Platelet counts (C) were determined from whole blood samples; alanine aminotransferase levels (ALT) (D)
were determined from serum at the indicated time points.
doi:10.1371/journal.pone.0036192.g003
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higher levels of MAb concentrations were detected in the serum of
the surviving animal (EBO3), remaining above 50 mg/ml until day
11 before IgG concentrations steadily increased (Figure 4A). This
increase is due to a challenge virus-induced IgG response against
ZEBOV proteins leading to recovery from infection as demon-
strated by the increase of nucleoprotein (NP)-specific IgGs
(Figure 4B). The concentration of MAb ch61 in the serum of
CTRL remained above 150 mg/ml until the animal had to be
euthanized on day 7 indicating no consumption of neutralizing
MAb through ZEBOV replication (Figure 4C).
Discussion
Passive transfer of antibodies leads to either complete inhibition
of virus replication, resulting in sterile immunity, or incomplete
protection in which the virus replicates at a reduced level, allowing
the host to mount virus-induced immune responses resulting in
virus clearance. In this study, passive transfer of a mixture of two
neutralizing MAbs conferred partial protection in rhesus ma-
caques against lethal ZEBOV challenge with 1 of 3 animals
surviving and another one showing delayed disease progression.
Our data demonstrate that animals can be protected even when
primary challenge virus replication occurs and that ‘‘sterile
immunity’’ is not necessarily required for protection from lethal
ZEBOV infection.
The GP gene of EBOV has two overlapping reading frames
expressing the full-length transmembrane GP and two nonstruc-
tural soluble GPs (sGP and ssGP), which are secreted from
ZEBOV-infected cells [21–24]. Due to its high abundance in the
blood of infected humans, it has been proposed that sGP facilitates
virus spread by deactivating anti-GP antibodies. Indeed, it has
been shown that sGP can reduce the neutralizing activities of anti-
GP serum in vitro [23]. A similar function was also suggested for the
shed GP ectodomain resulting from GP cleavage on the cell or
virus surface [25]. In this passive transfer study, serum MAb
concentrations dropped remarkably at the terminal stage of the
disease, indicating substantial consumption of these antibodies in
the blood. Since both MAbs used in this study do not bind sGP
dimers [15], this observation is likely due to uncontrolled virus
replication leading to production of large quantities of the shed
trimeric glycoprotein functioning as antibody decoy in the blood.
Therefore, it seems that high levels of plasma antibodies are
required to suppress virus replication until host immune responses
are sufficiently induced. This could be achieved through additional
injections (i.e. day 5 and day 7) or through higher MAb
concentrations in the initial injections. Complete neutralization
of ZEBOV using ch133 and ch226 in vitro was achieved at
concentrations of greater than 40 mg/ml (Figure 2). The antibody
dose used in this NHP study, which gave approximately 50–
100 mg/ml blood at each treatment, did not significantly differ
from the in vitro situation, but the half-life time of the MAb was
less than 4 days. This again indicates that more than three
injections (every 2–3 day) may have been beneficial. One possible
reason for relatively short half-life of our chimeric MAbs might be
reduced stability due to desialylation during the prolonged protein
expression process in CHO cell culture. In general, sialic acids
likely influence the solubility, thermal stability, and resistance to
protease attack of various glycoproteins. Thus, it seems possible
that the stability of MAbs may be improved by enhancing
sialylation during expression in CHO cells [26].
It has been demonstrated that EBOV utilizes multiple cellular
pathways for entry into host cells [27]. Direct inhibition of GP
attachment to cell surface or endosomal receptor(s) and blocking
fusion of viral and host membranes are likely to be key
mechanisms of neutralization. Preventing cathepsin cleavage is
another formal possibility but remains controversial [28,29]. The
Table 1. Virus titers in tissue samples collected from
euthanized animals during the prophylactic treatment study.
NHP ID Treatment
Time to
death [days] Liver Spleen
Adrenal
gland
CTRL ch61 7 8.53
a 8.38 8.24
BBO1 ch133+ch226 8 8.20 8.35 7.69
EBO2 ch133+ch226 11 7.32 6.75 7.05
EBO3 ch133+ch226 Survived ND
b ND ND
aVirus titers presented as log10 TCID50/gram tissue.
bND, not done.
doi:10.1371/journal.pone.0036192.t001
Figure 4. Serum antibody levels after ZEBOV challenge. Serum samples were collected from animals given the GP-specific MAb mixture or
ch61 during the period of the experiments of prophylactic treatments. Antibodies specific to GP (A), NP (B), and influenza virus HA (C) were detected
by ELISA, as described in Materials and Methods. Levels of anti-HA antibody were measured in the animal given only the control MAb (anti-HA, ch61).
Spontaneous induction of GP-specific IgG in the surviving animal after day 11 was detected due to cross-reactivity of the secondary antibody used in
the ELISA.
doi:10.1371/journal.pone.0036192.g004
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lethal ZEBOV challenge given a higher dose of MAb (50 mg/kg,
two times) [18] than that used in this NHP study (approximately
10–13 mg/kg, 3 times). Thus, the combination of two MAbs as
done in this study seems to have improved treatment efficacy at
lower antibody doses. Efficacy might be even higher with a
cocktail of three or more MAbs, in particular if they target distinct
epitopes and thus have independent mechanisms of action.
Previous studies on viral vector-based EBOV vaccine have
suggested that the induction of cellular immune responses is also
an important protective mechanism for EBOV infection [30,31].
Since dysfunction of the immune system is critical for the
pathogenesis of EHF in humans and NHPs [6,8,32], strategies
need to be developed improving the immune functions (both
humoral and cellular) disrupted during EHF. Thus, combined
treatment with neutralizing MAbs and immune-modulating
compounds should be evaluated in a future NHP study.
Materials and Methods
Challenge virus
ZEBOV (strain Kikwit) (kindly provided by the Centers for
Disease Control and Prevention, Atlanta, Georgia, USA) was
propagated in commonly used African green monkey kidney Vero
E6 cells (kindly provided by Dr. R. Baric, University of North
Carolina, Chapel Hill, NC, USA). The supernatants were cleared
of cell debris, aliquoted, and stored in liquid nitrogen until used.
All infectious work with ZEBOV was performed in the biosafety
level 4 (BSL-4) laboratories at the Integrated Research Facility in
the Rocky Mountain Laboratories (RML), Division of Intramural
Research, National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH), Hamilton, Mon-
tana, USA.
Monoclonal antibodies
Total RNA was extracted from mouse hybridoma cells
producing mouse MAb ZGP133/3.16 or ZGP226/8.1, both of
which were shown previously to neutralize ZEBOV [15,19]. The
variable heavy- and light-chain regions were amplified by RT-
PCR with primers designed for these antibodies. The PCR
products were subcloned into the pBR322-based plasmid, heavy-
and light-chain (IgG1) construction vectors (pDN11-g1 and pCB-
k, respectively), and the light chain cassette was transferred from
pCB-k into the heavy-chain expression vector pDN11-g1
(Figure 5). The resulting plasmids (pDN11-kg1) expressing
human-mouse chimeric MAbs ch133 and ch226 were designated
DN11-ch133kg1 and DN11-ch226kg1, respectively. Stable cell
lines expressing recombinant MAbs ch133 and ch226 were
obtained by transfection of CHO DG44 cells (Invitrogen) with
DN11-ch133kg1 and DN11-ch226kg1, respectively. Forty-eight
hours after transfection, cells were seeded at a density of 1610
3
cells/0.1 ml/well onto 96-well microculture plates in IS-CHO CD
medium (Irvine Scientific) containing G418 (400 mg/ml). Two
weeks after transfection, proliferating clones were isolated and
Figure 5. Scheme for the construction of pDN11-g1k. VH, heavy chain variable domain cDNA; VL, light chain variable domain cDNA; PAsv40,
simian virus 40 terminator; PRcmv, cytomegalovirus promoter; g1CH, constant domain of human IgG1; Ck constant domain of human kappa chain;
PRsv40d, enhancerless simian virus 40 promoter; NeoR, modified neomycin phosphotransferase gene; PAsv40, SV40 polyadenylation signal; PAbgh,
bovine growth hormone gene terminator; SPrbg, rabbit beta-globin intron; AmpR, b-lactamase gene; DHFR, dihydrofolate reductase cDNA; oriE,
replication origin of pBR322 plasmid.
doi:10.1371/journal.pone.0036192.g005
Passive Immunization against Ebola Virus Infection
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36192transferred to 24-well plates. Culture supernatants were collected
and analyzed for production of each MAb (ch133 and ch226)
by ELISA. For each MAb, the clone showing the highest
expression level was propagated further. A chimeric MAb (ch61)
specific for influenza virus hemagglutinin [strain A/Viet Nam/
1194/2004 (H5N1)] was generated as a control MAb using the
same methodology. MAb-expressing cell clones were maintained
in IS-CHO CD medium and the recombinant MAbs ch133,
ch226, and ch61 were purified from culture supernatants using
rProtein A Sepharose Fast Flow (GE Healthcare) and Endospecy
ES-50M (Seikagaku Biobusiness Corporation). MAb purity
(98%,) and endotoxin levels (,1.0 EU/ml) were confirmed by
performing SDS-PAGE and an EndoTrap red test (Profos AG),
respectively.
Neutralization assay
Vero E6 cells were seeded in a 48-well plate to generate a
confluent monolayer on the day of infection. MAb dilutions were
prepared in DMEM supplemented with 2% fetal bovine serum
and 25 ml were incubated with 200 focus forming units of ZEBOV
in a total volume of 50 ml. After 30 min at 37uC the media was
removed from cells, the serum-virus mixture was added and
incubated for 60 min at 37uC. Then the mixture was removed
from the cells and 0.5 ml of a 1.2% carboxymethyl cellulose
(CMC)/MEM (Life Technologies) solution was added per well.
Following incubation for 4 days at 37uC the plates were fixed with
10% neutral buffered formalin and removed from BSL4
laboratories according to standard operating procedures. Subse-
quently, the cells were permeabilized and foci were stained with a
rabbit anti-VP40 antibody (kindly provided by Dr. Y. Kawaoka,
University of Wisconsin, Madison, WI) followed by a FITC-
labeled secondary antibody (Sigma). Foci were counted using a
fluorescent microscope (Carl Zeiss Microimaging LLC).
Passive immunization and protection experiments
In the prophylactic treatment study, rhesus macaques (male
adults, 4.0–5.2 kg) were given a mixture of MAb ch133 and ch226
(25 mg each/animal; total of 50 mg per animal) (n=3) or ch61
(50 mg/animal) (n=1) intravenously 24 hours prior (day 21) to
challenge with an intramuscular injection of 10
3 plaque-forming
units of ZEBOV. The same amounts of antibodies were
administered again using the same route 24 and 72 hours after
challenge. Blood samples were collected throughout the study (on
days 21, 0, 1, 3, 5, 8, 11, 16, 21, 27, and 31), and used to
determine virus titers and antibody concentrations. Animals were
monitored daily for clinical signs (fever, posture, respiration, feces/
urine, food intake, recumbence, attitude, and skin turgor) using a
previously published scoring sheet approved by the local
Institutional Animal Care and Use Committee (IACUC) at
NIAID, NIH [33].
Hematology and serum biochemistry
The total white blood cell count, lymphocyte, platelet,
reticulocyte and red blood cell counts, hemoglobin, hematocrit
values, mean cell volume, mean corpuscular volume, and mean
corpuscular hemoglobin concentrations were determined from
EDTA blood with the HemaVet 950FS+ laser-based hematology
analyzer (Drew Scientific). Plasma biochemistry was analyzed
from heparin blood using the blood chemistry analyzer iSTAT1
(Abbott Point of Care). Urea nitrogen, glucose, chloride, sodium,
potassium, hematocrit, hemoglobin, pH, PCO2, TCO2, base
excess, and anion gap values were determined using the EC8+
Cartridge. Creatinine values were evaluated using Crea cartridges.
Enzyme-linked immunosorbent assay (ELISA)
The filovirus GP-based ELISA was performed as described
previously [34]. Briefly, ELISA plates (Nunc Maxisorp) were
coated with purified soluble ZEBOV GP lacking transmembrane
domain (100 ng/50 ml/well), followed by blocking with 3% skim
milk (200 ml/well). Serial dilutions of NHP serum samples and
purified antibodies (ch133, ch226, and ch61) of known concen-
trations were prepared, added to the ELISA plates and incubated
for 1 hour at room temperature. Bound antibodies were visualized
by adding a secondary peroxidase-conjugated goat anti-human
IgG Fcc fragment antibody (Jackson ImmunoResearch) and
3,39,5,59-tetramethylbenzidine (Sigma). The addition of 1 M
phosphoric acid stopped the reaction and the optical density
(OD) at 450 nm was measured. Antibody concentrations in the
NHP serum samples were determined based on the OD values
obtained for the standard curves from purified ch133, ch226, and
ch61. For ch61, A/Viet Nam/1194/2004 (H5N1) virus particles
treated with 0.5% Triton X-100 were used as the ELISA antigen.
ZEBOV NP-specific antibodies in the serum samples (1:10000
dilution) were detected performing ELISA using a recombinant
NP antigen [35] and peroxidase-conjugated goat anti-monkey IgG
c chain antibody (Rockland).
Virus detection
Total RNA was isolated from whole blood samples using the
QIAmp viral Mini RNA kit (Qiagen). All quantitative real-time
RT-PCRs were performed by employing the QIAquick 1-step
Rotorgene kit (Qiagen) and ZEBOV-specific primers and probes
based on the nucleoprotein sequence (NP; bp 2661–2721,
GenBank accession number AF086833). We performed virus
titration by TCID50 in Vero E6 cells from the blood and selected
tissue samples. Briefly, 10-fold serial dilutions of the blood and
tissue homogenates were prepared and used to infect Vero E6
cells. Cells were monitored for cytopathic effects (CPE) and the
TCID50 was calculated for each sample employing the Reed and
Muench method [36].
Animal ethics statement
Healthy, adult rhesus macaques (Macaca mulatta) were handled
in the Rocky Mountain Laboratories (RML) Animal BSL-2 and
BSL-4 containment space. Research was conducted in compliance
with the Animal Welfare Act and other federal statutes and
regulations relating to animals and experiments involving animals,
and adhered principles stated in the Guide for the Care and Use of
Laboratory Animals, National Research Council, 1996. The
facility where this research was conducted (RML) is fully
accredited by the Association for the Assessment and Accredita-
tion of Laboratory Animal Care International and has an
approved OLAW Assurance #A4149-01. Research was conduct-
ed under a protocol approved by the IACUC. All steps were taken
to ameliorate the welfare and to avoid the suffering of the animals
in accordance with the ‘‘Weatherall report for the use of non-
human primates’’ recommendations. Animals were housed in
adjoining individual primate cages allowing social interactions,
under controlled conditions of humidity, temperature and light
(12-hour light/12-hour dark cycles). Food and water were
available ad libitum. Animals were monitored (pre- and post-
infection) and fed commercial monkey chow, treats and fruit twice
daily by trained personnel. Environmental enrichment consisted of
commercial toys. All procedures were conducted by trained
personnel under the supervision of veterinarians and all invasive
clinical procedures were performed while animals were anesthe-
tized. Early endpoint criteria, as specified by the IACUC approved
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humanely euthanized.
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